SEC Filing Summary: Medasorb Technologies Corporation (8-K)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Medasorb Technologies Corporation (Nevada) on February 14, 2007, covering events occurring on February 8, 2007. The registrant is headquartered in Monmouth Junction, New Jersey.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on a corporate governance event regarding executive compensation.
Material Changes
On February 8, 2007, the Board of Directors approved a compensatory arrangement for Al Kraus, the President and Chief Executive Officer. The grant consists of an immediately exercisable option to purchase 400,000 shares of common stock at an exercise price of $1.26 per share, which was the closing price on the date of the grant.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies beyond the specific executive compensation grant detailed in Item 5.02.
Investor Verification Points
- Verify the total number of outstanding shares and the potential dilution impact of the 400,000 new options granted.
- Confirm the current market price of the stock relative to the $1.26 exercise price to assess the immediate value of the grant.
- Review the company's most recent 10-K or 10-Q filings for financial performance data, as this 8-K does not contain financial results.